524516 BACPHAR

Bacil Pharma Share Price

₹37.32 +0.73 (2%)

18 Mar, 2025 03:38

SIP TrendupStart SIP in BACPHAR

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume

Investment Returns

  • Over 1 Month -14.66%
  • Over 3 Month -36.71%
  • Over 6 Month + 57.53%
  • Over 1 Year + 198.32%
SIP Lightning

Smart Investing Starts Here Start SIP with Bacil Pharma for Steady Growth!

Invest Now

Bacil Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Bacil Pharma Financials

Bacil Pharma Technicals

EMA & SMA

Current Price
₹37.32
+ 0.73 (2%)
pointer
  • stock-down_img
  • Bearish Moving Average 11
  • stock-up_img
  • Bullish Moving Average 5
  • 20 Day
  • ₹39.32
  • 50 Day
  • ₹42.27
  • 100 Day
  • ₹41.76
  • 200 Day
  • ₹36.03

Resistance and Support

37.82 Pivot Speed
  • R3 39.41
  • R2 38.90
  • R1 38.33
  • S1 37.25
  • S2 36.74
  • S3 36.17

What's your outlook on Bacil Pharma?

You can only vote for once

Bacil Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-21 Quarterly Results
2024-10-23 Quarterly Results
2024-10-15 Others
2024-09-27 Increase in Authorised Capital
2024-08-14 Quarterly Results

Bacil Pharma F&O

Bacil Pharma Shareholding Pattern

No data available.

About Bacil Pharma

  • NSE Symbol
  • BACPHAR
  • BSE Symbol
  • 524516
  • ISIN
  • INE711D01018

Similar Stocks to Bacil Pharma

Bacil Pharma FAQs

Bacil Pharma share price is ₹37 As on 18 March, 2025 | 03:24

The Market Cap of Bacil Pharma is ₹22 Cr As on 18 March, 2025 | 03:24

The P/E ratio of Bacil Pharma is 63.1 As on 18 March, 2025 | 03:24

The PB ratio of Bacil Pharma is 38.2 As on 18 March, 2025 | 03:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23